Ifosfamide

A technical problem at the site manufacturing the ifosfamide-containing medicines, together with site improvements required after a regulatory inspection in September 2025, led to a short pause in the manufacture and release of ifosfamide. Although manufacturing has now resumed at the facility, the pause led to a shortage that is expected to continue until Q1 2027, when the manufacturing site is expected to return to full capacity.

The shortage is not related to a quality defect of the product or a safety issue.

The shortage is likely to affect all EU/EEA Member States.

For up-to-date information about the status of a medicine shortage in a particular Member State, consult the national shortage register or contact the national competent authority.

EMA is closely monitoring the supply situation of ifosfamide and alternative medicines, and is engaging with Baxter, alternative manufacturers and international regulators to mitigate the impact of the shortage.

Monitoring is carried out by EMA’s Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) and shortages working party (Medicines Shortages Single Point of Contact – SPOC - working party). For further information see ‘related information’.

• There is an ongoing shortage of ifosfamide (marketed as Holoxan and other names) affecting all EU/EEA Member States that is expected to last until Q1 2027.
• Before starting treatment, healthcare professionals should ensure that sufficient supplies are available to complete a treatment course.
• If ifosfamide is not available, healthcare professionals should consider switching their patients to another medicine, depending on the availability of a suitable alternative therapy and in line with relevant clinical guidelines.
• For additional information, consult your country’s shortage register or contact your national competent authority.
• You may also contact relevant healthcare professional organisations for further information. A list of European not-for-profit organisations with which EMA engages can be found on this website.
• A medicine shortage communication (MSC) with detailed guidance has been sent to healthcare professionals in affected Member States and is also published on this website.

• There is an ongoing shortage of ifosfamide-containing medicines (marketed as Holoxan and other names) affecting all EU/EEA countries that is expected to last until first quarter of 2027.
• Your doctor will check that there are sufficient supplies available before starting treatment with ifosfamide.
• If ifosfamide is not available, your healthcare professional will discuss the treatment options with you.
• You may also contact relevant patients’ organisations for further information or support. A list of European not-for-profit organisations that EMA engages with can be found on the EMA website.